Mohamad Gabriel Alameh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5111310/publications.pdf

Version: 2024-02-01

29 papers

2,139 citations

361296 20 h-index 27 g-index

32 all docs

32 docs citations

times ranked

32

2746 citing authors

#	Article	IF	Citations
1	Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery. Journal of Controlled Release, 2022, 341, 616-633.	4.8	29
2	Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery. Journal of Controlled Release, 2022, 341, 206-214.	4.8	27
3	Rational design of antiâ€inflammatory lipid nanoparticles for mRNA delivery. Journal of Biomedical Materials Research - Part A, 2022, 110, 1101-1108.	2.1	23
4	Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine. Viruses, 2022, 14, 540.	1.5	6
5	Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens. , 2022, , 141-169.		4
6	Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells. Journal of Controlled Release, 2022, 347, 521-532.	4.8	33
7	Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment. Journal of the American Chemical Society, 2022, 144, 9926-9937.	6.6	46
8	Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response. Journal of Virology, 2022, 96, .	1.5	7
9	Purification and Surface Modification of Chitosan-based Polyplexes Using Tangential Flow Filtration and Coating by Hyaluronic Acid. Journal of Pharmaceutical Sciences, 2022, 111, 2857-2866.	1.6	O
10	Quality of Cartilage Repair from Marrow Stimulation Correlates with Cell Number, Clonogenic, Chondrogenic, and Matrix Production Potential of Underlying Bone Marrow Stromal Cells in a Rabbit Model. Cartilage, 2021, 12, 237-250.	1.4	9
11	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host and Microbe, 2021, 29, 23-31.e4.	5.1	308
12	Ionizable lipid nanoparticles for in utero mRNA delivery. Science Advances, 2021, 7, .	4.7	110
13	Highly efficient CD4+ TÂcell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Molecular Therapy, 2021, 29, 3293-3304.	3.7	88
14	Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device. Nano Letters, 2021, 21, 5671-5680.	4.5	120
15	Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Communications Biology, 2021, 4, 956.	2.0	151
16	Poly(2-Propylacrylic Acid) Increases In Vitro Bioactivity of Chitosan/mRNA Nanoparticles. Journal of Pharmaceutical Sciences, 2021, 110, 3439-3449.	1.6	7
17	Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines, 2021, 9, 65.	2.1	310
18	Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models. Journal of Clinical Investigation, 2021, 131, .	3.9	17

#	Article	IF	CITATIONS
19	Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity, 2021, 54, 2877-2892.e7.	6.6	260
20	Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines, 2021, 9, 1490.	2.1	48
21	An ionizable lipid toolbox for RNA delivery. Nature Communications, 2021, 12, 7233.	5.8	182
22	Efficiency of Chitosan/Hyaluronan-Based mRNA Delivery Systems InÂVitro: Influence of Composition and Structure. Journal of Pharmaceutical Sciences, 2020, 109, 1581-1593.	1.6	25
23	Messenger RNA-Based Vaccines Against Infectious Diseases. Current Topics in Microbiology and Immunology, 2020, , 111-145.	0.7	43
24	siRNA Delivery with Chitosan: Influence of Chitosan Molecular Weight, Degree of Deacetylation, and Amine to Phosphate Ratio on in Vitro Silencing Efficiency, Hemocompatibility, Biodistribution, and in Vivo Efficacy. Biomacromolecules, 2018, 19, 112-131.	2.6	91
25	Automated in-line mixing system for large scale production of chitosan-based polyplexes. Journal of Colloid and Interface Science, 2017, 500, 253-263.	5.0	15
26	Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery. International Journal of Nanomedicine, 2012, 7, 1399.	3.3	49
27	Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes. European Journal of Pharmaceutical Sciences, 2012, 45, 138-149.	1.9	64
28	Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes. Gene Therapy, 2011, 18, 807-816.	2.3	40
29	Chitosanase-based method for RNA isolation from cells transfected with chitosan/siRNA nanocomplexes for real-time RT-PCR in gene silencing. International Journal of Nanomedicine, 2010, 5, 473.	3.3	21